Ad
related to: novartis ain457 patient treatment- Contact Us
For questions about treatment and
our support program, call us today
- Alnylam Assist Enrollment
Complete the Start Form
with your patient to enroll them
- Patient Enrollment
Get started today and enroll your
patients to get ongoing support
- Contact the Team
Discover how the Alnylam Assist®
team can help your patients
- Contact Us
Search results
Results From The WOW.Com Content Network
Secukinumab. Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. [4] [5] [6] It binds to the protein interleukin (IL)-17A and is marketed by Novartis. [4] [5] [6]
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer). Serious side effects occur in most patients.
Nilotinib. Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [4] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.
The global optic nerve disorders treatment market size was valued at US$3.4 billion in 2021, and is projected to reach US$5.3 billion by 2031, growing at a Compound Annual Growth Rate of 4.5% from 2022 to 2031.
In many cases, Imatinib can induce a complete cytogenetic response (CCyR) and major molecular response (MMR) and many patients can have a long-term remission. It is also used to maintain remission in chronic phase CML patients. While Imatinib is a very effective treatment for CML and some types of ALL, it is not a cure for leukemia.
DelveInsight’s PDE4 Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging PDE4 inhibitors, market share of individual therapies, and current and forecasted PDE4 Inhibitor market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany ...
Lapatinib. Lapatinib ( INN ), used in the form of lapatinib ditosylate ( USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours. [2] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. [3]
Ianalumab. Ianalumab ( INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II ...
Ad
related to: novartis ain457 patient treatment